Abstract
Therapeutics targeting sphingosine-1-phosphate (S1P), a kind of lipid mediator regulating immune cell trafficking, has been emerging rapidly as a novel line of regimen for autoimmune diseases, including rheumatoid arthritis (RA). Here, we propose that S1P-targeted therapy is beneficial not only for limiting inflammation but for preventing bone-resorptive disorders, such as osteoporosis, by controlling the migratory behavior of osteoclast precursors and therefore would be good for treating elderly female RA patients who suffer from postmenopausal osteoporosis and arthritis simultaneously.
MeSH terms
-
Age Factors
-
Aged
-
Animals
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Arthritis, Rheumatoid / complications
-
Arthritis, Rheumatoid / drug therapy*
-
Female
-
Humans
-
Lysophospholipids / agonists*
-
Lysophospholipids / physiology
-
Mice
-
Osteoclasts / drug effects*
-
Osteoclasts / physiology
-
Osteoporosis, Postmenopausal / drug therapy*
-
Osteoporosis, Postmenopausal / immunology
-
Receptors, Lysosphingolipid / agonists*
-
Receptors, Lysosphingolipid / physiology
-
Sphingosine / agonists
-
Sphingosine / analogs & derivatives*
-
Sphingosine / physiology
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Lysophospholipids
-
Receptors, Lysosphingolipid
-
sphingosine 1-phosphate
-
Sphingosine